Oncolys BioPharma, Inc. (JP:4588)
:4588
Want to see JP:4588 full AI Analyst Report?
Top Page
Oncolys BioPharma, Inc.
(4588)
Select Model
Select Model
Rating:55Neutral
Price Target:
¥2,403.00
▲(152.15% Upside)
Action:Reiterated
Date:03/03/26
The score is held down primarily by weak financial performance—collapsed revenue, persistent large losses, and heavy cash burn—despite a relatively manageable balance sheet. Strong technical momentum lifts the score, while valuation remains constrained by loss-making economics and no dividend support.
Positive Factors
Manageable leverage
Improved debt-to-equity (~0.12) indicates relatively low financial leverage versus peers, giving the company structural flexibility to raise capital or absorb shocks while advancing clinical programs. Lower leverage reduces short-term default risk and preserves strategic optionality amid losses.
Negative Factors
Collapsed revenue trend
Dramatic multi-year revenue decline erodes the business base and shows failure to scale commercial activities. Structurally low revenue relative to fixed R&D and SG&A means the company cannot self-fund growth, making sustained development dependent on external financing or transformational revenue inflection.
Read all positive and negative factors
Positive Factors
Negative Factors
Manageable leverage
Improved debt-to-equity (~0.12) indicates relatively low financial leverage versus peers, giving the company structural flexibility to raise capital or absorb shocks while advancing clinical programs. Lower leverage reduces short-term default risk and preserves strategic optionality amid losses.
Read all positive factors
Oncolys BioPharma, Inc. (4588) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥78.43B
Dividend YieldN/A
Average Volume (3M)1.52M
Price to Earnings (P/E)―
Beta (1Y)2.11
Revenue Growth0.80%
EPS Growth32.87%
CountryJP
Employees40
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-93.11
Shares Outstanding29,302,700
10 Day Avg. Volume2,742,450
30 Day Avg. Volume1,517,566
Financial Highlights & Ratios
PEG Ratio-4.72
Price to Book (P/B)8.90
Price to Sales (P/S)1247.26
P/FCF Ratio-18.32
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Oncolys BioPharma, Inc. Business Overview & Revenue Model
Company Description
Oncolys BioPharma Inc. engages in the research, development, manufacture, sale, import, and export of oncolytic viruses, drugs and medicines, and tumor diagnostic agents in Japan, the rest of Asia, and the United States. Its product pipeline inclu...
How the Company Makes Money
null...
Oncolys BioPharma, Inc. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
21
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 28.55M | 28.55M | 31.38M | 63.04M | 976.18M | 642.49M |
| Gross Profit | 27.68M | 28.30M | 31.38M | 30.61M | 338.49M | 198.80M |
| EBITDA | -2.18B | -2.05B | -1.68B | -1.93B | -1.14B | -1.60B |
| Net Income | -2.24B | -2.06B | -1.68B | -1.94B | -1.15B | -1.62B |
Balance Sheet | ||||||
| Total Assets | 1.93B | 4.56B | 3.20B | 2.04B | 2.65B | 4.29B |
| Cash, Cash Equivalents and Short-Term Investments | 1.39B | 3.72B | 2.41B | 1.53B | 1.71B | 3.45B |
| Total Debt | 366.79M | 320.02M | 324.64M | 315.17M | 393.66M | 503.47M |
| Total Liabilities | 493.35M | 555.91M | 446.65M | 566.50M | 491.69M | 697.88M |
| Stockholders Equity | 1.44B | 4.00B | 2.75B | 1.47B | 2.16B | 3.59B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -1.94B | -2.02B | -1.34B | -1.72B | -1.74B |
| Operating Cash Flow | 0.00 | -1.94B | -2.02B | -1.34B | -1.72B | -1.74B |
| Investing Cash Flow | 0.00 | -7.58M | -4.71M | -5.39M | 20.12M | -942.00K |
| Financing Cash Flow | 0.00 | 3.22B | 2.88B | 1.14B | -113.83M | 3.09B |
Oncolys BioPharma, Inc. Technical Analysis
Positive
953.00
Price Trends
2474.40
Positive
1881.31
Positive
1283.93
Positive
Market Momentum
58.28
Negative
61.52
Neutral
88.21
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4588, the sentiment is Positive. The current price of 953 is below the 20-day moving average (MA) of 2416.70, below the 50-day MA of 2474.40, and below the 200-day MA of 1283.93, indicating a bullish trend. The MACD of 58.28 indicates Negative momentum. The RSI at 61.52 is Neutral, neither overbought nor oversold. The STOCH value of 88.21 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4588.
Oncolys BioPharma, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | ¥78.43B | -38.09 | ― | ― | 0.80% | 32.87% | |
54 Neutral | ¥137.64B | -14.40 | ― | 2.18% | -10.48% | -1022.09% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | ¥13.11B | -11.52 | ― | ― | ― | 24.17% | |
47 Neutral | ¥6.87B | -9.98 | ― | ― | -23.82% | 14.80% | |
46 Neutral | ¥146.31B | -45.25 | -10.16% | ― | -59.19% | -124.16% | |
45 Neutral | ¥7.97B | -7.57 | -63.25% | ― | 7.80% | 12.92% |
* Healthcare Sector Average
JP:4588
Oncolys BioPharma, Inc.
2,680.00
2,148.00
403.76%
JP:4587
Peptidream
1,127.00
-668.00
-37.21%
JP:4564
OncoTherapy Science
20.00
-2.00
-9.09%
JP:4575
CanBas Co., Ltd.
665.00
-487.00
-42.27%
JP:4583
Chiome Bioscience Inc.
92.00
-56.00
-37.84%
JP:4974
Takara Bio Inc.
1,143.00
362.00
46.35%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.